Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized antithrombotic strategies for non-thrombolysed atherosclerotic acute cerebral infarction
ChiCTR2400080375Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of argatroban, aspirin and clopidogrel in ischemic stroke and brain infarction (2 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: Good prognosis. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
argatrobanaspirinclopidogrel
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on ChiCTR2400080375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080375.